How bright is the future for Digital Therapeutics across Europe? By Candesic Ltd
https://impactx2050.com/x-report-april-may-2023?utm_campaign=X%20Report&utm_medium=email&_hsmi=257768105&_hsenc=p2ANqtz-9_Q4KLnNsc8aCNNWTXAn0GxnHYV9uz7bIlPniEzeek_jwGWAJLVzndZxGv8nuSf906qQJQwmUZeKWdkg

Candesic partners Marc Kitten and Dr Michelle Tempest cover rapidly growing DTx Europe market in the newest ImpactX2050 report powered by IBIS Capital & Tyton Partners.

Candesic investigates current state of Digital Therapeutics, its opportunities, implications and what`s next.

Click on the link to read more.

About

Candesic is a leading strategy consultancy head-quartered in London, serving private operators, investors, and public sector organisations.

Privacy

Privacy Policy

News & Publications

Candesic advisor Professor Stephen Smith as a speaker at The Women's Health Technology event
Candesic advisor Professor Stephen Smith spoke at a The Women`s Health Technology GIANT Health Event in London. His participation in the panel on "How do various sectors in Women's Health overcome barriers to meaningful progress?" was moderated by Professor Dame Lesley Regan and delved into the key reasons the gender gap exists in healthcare. Professor Stephen Smith has a wealth of experience in the area among other things as a Former Professor of Obstetrics and Gynaecology at Cambridge University. Click on the link to find out more about the event.

Dr Michelle Tempest featured in the new Financial Times
Dr Michelle Tempest, Senior Partner at Candesic, featured in the Financial Times discussing the implications of increased reliance of the NHS on private providers. Private sector outsourcing has become a critical element for the NHS to deliver patient care, and while it is currently resulting in improved outcomes for patients, to address the underlying structural issues will require continued public and private investment. Click on the link to subscribe and read more.

Candesic provided commercial due diligence to Ampersand Capital Partners
Congratulations to the Ampersand Capital Partners team on their investment in Julius Clinical Research! Candesic provided commercial due diligence to Ampersand Capital Partners. Julius Clinical is a leading academic clinical CRO providing clinical trial services and real-world evidence studies to biopharma sponsors. This strategic partnership will enhance Julius Clinical capabilities in pioneering clinical research and support the development of new therapeutics on a global scale.

© Candesic 2023